IN2012DN02993A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02993A
IN2012DN02993A IN2993DEN2012A IN2012DN02993A IN 2012DN02993 A IN2012DN02993 A IN 2012DN02993A IN 2993DEN2012 A IN2993DEN2012 A IN 2993DEN2012A IN 2012DN02993 A IN2012DN02993 A IN 2012DN02993A
Authority
IN
India
Prior art keywords
ebv
provides
present
cell
tcr
Prior art date
Application number
Other languages
English (en)
Inventor
Stauss Hans
Xue Shao-An
Topp Max
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of IN2012DN02993A publication Critical patent/IN2012DN02993A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN2993DEN2012 2009-09-29 2010-09-28 IN2012DN02993A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0917090.3A GB0917090D0 (en) 2009-09-29 2009-09-29 T-cell receptor
PCT/GB2010/001821 WO2011039508A2 (en) 2009-09-29 2010-09-28 T-cell receptor

Publications (1)

Publication Number Publication Date
IN2012DN02993A true IN2012DN02993A (enExample) 2015-07-31

Family

ID=41350560

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2993DEN2012 IN2012DN02993A (enExample) 2009-09-29 2010-09-28

Country Status (10)

Country Link
US (1) US8889141B2 (enExample)
EP (1) EP2483294B1 (enExample)
JP (2) JP6180114B2 (enExample)
KR (1) KR101760277B1 (enExample)
CN (1) CN102695717B (enExample)
AU (1) AU2010302477B2 (enExample)
ES (1) ES2584541T3 (enExample)
GB (1) GB0917090D0 (enExample)
IN (1) IN2012DN02993A (enExample)
WO (1) WO2011039508A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2772076A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
EP2694640B1 (en) 2011-04-08 2017-10-18 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
RS61455B1 (sr) 2011-10-28 2021-03-31 Regeneron Pharma Genetski modifikovani miševi t ćelijskog receptora
BR112014014591A8 (pt) 2011-12-12 2017-07-04 Baylor College Medicine processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2812431B1 (en) 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
EP3495483A1 (en) 2012-09-12 2019-06-12 International Institute of Cancer Immunology, Inc. Antigen-specific helper t-cell receptor genes
CN110511960B (zh) * 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
PT3149031T (pt) * 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
WO2015199618A1 (en) * 2014-06-24 2015-12-30 National University Of Singapore Epstein-barr virus lmp2 specific antibody and uses thereof
PL3212225T3 (pl) 2014-10-31 2026-03-30 The Trustees Of The University Of Pennsylvania Sposoby i kompozycje zmodyfikowanych limfocytów t
WO2016095783A1 (zh) * 2014-12-17 2016-06-23 中国科学院广州生物医药与健康研究院 识别eb病毒短肽的t细胞受体
CA2971677A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
MX2017012829A (es) 2015-04-06 2018-02-23 Regeneron Pharma Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.
CN104830793A (zh) * 2015-05-05 2015-08-12 杨光华 基于lmp-1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途
IL281396B (en) * 2015-06-09 2022-07-01 Memorial Sloan Kettering Cancer Center T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
KR101794304B1 (ko) 2015-09-01 2017-11-06 가톨릭대학교 산학협력단 Ｅｂｖ 항원 특이 ｔ―세포 수용체 및 이의 용도
US11167024B2 (en) 2015-09-18 2021-11-09 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
GB201520191D0 (en) * 2015-11-16 2015-12-30 Cancer Rec Tech Ltd T-cell receptor and uses thereof
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
CN109963860A (zh) * 2016-09-19 2019-07-02 拜耳作物科学股份公司 吡唑并[1,5-a]吡啶衍生物及其作为农药的用途
CN108218976B (zh) * 2016-12-09 2021-11-05 香雪生命科学技术（广东）有限公司 衍生自lmp1的肿瘤抗原短肽
WO2019031938A2 (ko) 2017-08-10 2019-02-14 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
EP3773633A4 (en) 2018-04-06 2022-01-26 The Regents of The University of California METHODS OF TREATMENT OF GLIOBLASTOMA
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
SG11202101671PA (en) 2018-11-27 2021-03-30 Univ Duke Anti-lmp2 tcr-t cell therapy for the treatment of ebv-associated cancers
WO2020133050A1 (zh) * 2018-12-27 2020-07-02 深圳华大生命科学研究院 Ebv表位高亲和力t细胞受体
EP3786178A1 (en) * 2019-08-30 2021-03-03 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for ebv-derived antigens
WO2021211455A1 (en) * 2020-04-13 2021-10-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against lmp2
WO2021243695A1 (en) * 2020-06-05 2021-12-09 Guangdong Tcrcure Biopharma Technology Co., Ltd. Tcr-t cell therapy targeting epstein-barr virus
EP3940075A1 (en) * 2020-07-17 2022-01-19 Istituto Nazionale Di Genetica Molecolare-INGM Inhibitors of line1 and uses thereof
CN116981357A (zh) 2021-03-31 2023-10-31 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
EP4091627A1 (en) 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
CN113773378B (zh) * 2021-10-14 2023-11-03 深圳大学总医院 T细胞受体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101182531B (zh) * 2007-11-09 2010-06-02 暨南大学 Eb病毒特异性tcr基因相关的重组质粒及构建抗ebv特异性ctl的方法

Also Published As

Publication number Publication date
US20120244132A1 (en) 2012-09-27
EP2483294B1 (en) 2016-07-13
CN102695717B (zh) 2016-08-10
GB0917090D0 (en) 2009-11-11
JP2016047064A (ja) 2016-04-07
AU2010302477B2 (en) 2017-01-19
US8889141B2 (en) 2014-11-18
KR101760277B1 (ko) 2017-07-21
WO2011039508A3 (en) 2011-06-30
EP2483294A2 (en) 2012-08-08
WO2011039508A2 (en) 2011-04-07
JP2013505734A (ja) 2013-02-21
AU2010302477A1 (en) 2012-04-19
CN102695717A (zh) 2012-09-26
JP6180114B2 (ja) 2017-08-16
ES2584541T3 (es) 2016-09-28
KR20120074291A (ko) 2012-07-05

Similar Documents

Publication Publication Date Title
WO2011039508A3 (en) T-cell receptor
ZA202006432B (en) T cell receptors
MX350126B (es) Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo.
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
PH12016500272A1 (en) T cell receptors
NZ600732A (en) Oxyntomodulin peptide analogue
NZ598356A (en) Antigenic tau peptides and uses thereof
HRP20240676T1 (hr) Proteini domena skele na bazi fibronektina koji vezuju miostatin
WO2013151672A3 (en) Modified polynucleotides for the production of oncology-related proteins and peptides
JP2017514522A5 (enExample)
NZ706884A (en) Fc gamma receptor iib variants
MX377650B (es) Vacuna y métodos para reducir una infección por campylobacter.
NZ705899A (en) Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof
NZ599590A (en) Factor involved in latent infection with herpesvirus, and use thereof
JP2013505734A5 (enExample)
NZ629309A (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
MX2009007261A (es) Vacuna de peptido foxp3.
NZ586074A (en) LCLRP peptides, constructs and uses thereof
Koh et al. Degradation-resistant protein domains limit host cell processing and immune detection of mycobacteria
MX2010005816A (es) Epítopos de péptido de stat3.
JP2015527074A5 (enExample)
EA201390811A1 (ru) Пептиды tomm34 и содержащие их вакцины
NZ603611A (en) Insulin-like growth factor 1 receptor binding peptides
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same